{"id":745745,"date":"2018-03-23T06:00:00","date_gmt":"2018-03-23T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/"},"modified":"2025-11-07T01:27:25","modified_gmt":"2025-11-07T06:27:25","slug":"anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/","title":{"rendered":"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC"},"content":{"rendered":"<p class=\"bwalignc\">       First New Front-Line Treatment Option for HCC Approved in Japan in        Nearly 10 Years     <\/p>\n<p class=\"bwalignc\">       First Approval Under Global Strategic Collaboration Between Eisai        Co., Ltd. and Merck     <\/p>\n<p>\n      Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United<br \/>\n      States and Canada, today announced that the multiple receptor tyrosine<br \/>\n      kinase inhibitor LENVIMA<sup>\u00ae<\/sup> (lenvatinib mesylate) has been<br \/>\n      approved in Japan for unresectable hepatocellular carcinoma (HCC). This<br \/>\n      is the first approval worldwide for LENVIMA for the indication of<br \/>\n      unresectable HCC and the first new systemic therapy to be approved in<br \/>\n      Japan for the front line treatment of HCC in approximately 10 years.<br \/>\n      Additionally, this is the first regulatory approval for LENVIMA under<br \/>\n      the global strategic collaboration agreement executed in March 2018<br \/>\n      between Eisai and Merck for the co-development and co-commercialization<br \/>\n      of LENVIMA.\n    <\/p>\n<p>\n      This approval was based on a phase 3 clinical study (Study 304\/REFLECT<br \/>\n      study) conducted by Eisai investigating LENVIMA as a first-line<br \/>\n      treatment in patients with unresectable HCC. In this study, LENVIMA<br \/>\n      demonstrated statistically significant non-inferiority of overall<br \/>\n      survival (OS) (13.6 months) compared to sorafenib (12.3 months) (hazard<br \/>\n      ratio [HR] 0.92, 95% confidence interval [CI]=0.79-1.06). Additionally,<br \/>\n      LENVIMA showed highly statistically significant and clinically<br \/>\n      meaningful improvements as compared to sorafenib in the secondary<br \/>\n      endpoints of progression-free survival (PFS) (HR 0.66, 95% CI=0.57-0.77,<br \/>\n      p&lt;0.00001), time to progression (TTP) (HR 0.63, 95% CI=0.53-0.73,<br \/>\n      p&lt;0.00001), and objective response rate (ORR) (LENVIMA 24% versus<br \/>\n      sorafenib 9%, p&lt;0.00001). Furthermore, LENVIMA helped to delay<br \/>\n      deterioration in several quality of life (QOL) and symptom domains<br \/>\n      (pre-specified secondary endpoint), including in areas such as pain and<br \/>\n      diarrhea, compared to sorafenib (nominal p-value&lt;0.05).\n    <\/p>\n<p>\n      In this study, the five most common adverse events observed in the<br \/>\n      LENVIMA arm were hypertension (42%), diarrhea (39%), decreased appetite<br \/>\n      (34%), weight loss (31%) and fatigue (30%), which is consistent with the<br \/>\n      known safety profile of LENVIMA.\n    <\/p>\n<p>\n      Liver cancer is the second leading cause of cancer-related deaths, with<br \/>\n      approximately 750,000 deaths per year estimated globally. Additionally,<br \/>\n      approximately 780,000 cases are newly diagnosed each year, about 80<br \/>\n      percent of which occur in Asia, including Japan and China. HCC accounts<br \/>\n      as the primary reason for 85 percent to 90 percent of liver cancer<br \/>\n      cases. It is estimated that there are approximately 42,000 HCC patients<br \/>\n      in Japan, with approximately 26,000 deaths every year. To date,<br \/>\n      treatment options for unresectable HCC have been limited, and the<br \/>\n      prognosis is very poor, emphasizing that this is an area of high unmet<br \/>\n      medical need.\n    <\/p>\n<p>\n      \u201cWith the approval of this additional indication of unresectable HCC for<br \/>\n      LENVIMA, we are proud to be able to deliver the first new front-line<br \/>\n      systemic therapy treatment option for HCC in Japan in approximately 10<br \/>\n      years, and expect this will contribute to HCC treatment,\u201d said Dr.<br \/>\n      Takashi Owa, Eisai Oncology Business Group Chief Medicine Creation<br \/>\n      Officer. \u201cEisai will continue with its efforts in oncology research and<br \/>\n      development in order to deliver hopes for a potential cure for cancer to<br \/>\n      patients and their families.\u201d\n    <\/p>\n<p>\n      \u201cToday\u2019s approval is an important first for LENVIMA and a significant<br \/>\n      first regulatory event under our collaboration with Eisai,\u201d said Dr. Roy<br \/>\n      Baynes, Senior Vice President and Head of Global Clinical Development,<br \/>\n      Chief Medical Officer, Merck Research Laboratories. \u201cWe congratulate<br \/>\n      Eisai on the approval of this new indication and look forward to working<br \/>\n      together to bring this important treatment option to patients.\u201d\n    <\/p>\n<p>\n      Having received approval of this indication, Eisai will receive a<br \/>\n      development milestone payment from Merck. There are no changes to<br \/>\n      Eisai\u2019s consolidated financial results forecasts for the fiscal year<br \/>\n      ending March 31, 2018 based on the receipt of this milestone payment.\n    <\/p>\n<p>\n      <b>LENVIMA Product Details in Japan (underlined parts have been added)<\/b>\n    <\/p>\n<p>\n      1) Product name\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae<\/sup> Capsule 4 mg\n    <\/p>\n<p>\n      2) Generic name\n    <\/p>\n<p>\n      Lenvatinib mesylate\n    <\/p>\n<p>\n      3) Indication\n    <\/p>\n<p>\n      Unresectable thyroid cancer, <span class=\"bwuline\">unresectable<br \/>\n      hepatocellular carcinoma<\/span>\n    <\/p>\n<p>\n      4) Dosage and Administration\n    <\/p>\n<p>\n      Unresectable thyroid cancer\n    <\/p>\n<p>\n      The usual adult dose is 24 mg as lenvatinib administered orally once a<br \/>\n      day. The dose may be reduced depending on the condition of the<br \/>\n      individual patient.\n    <\/p>\n<p>\n      <span class=\"bwuline\">Unresectable hepatocellular carcinoma<\/span>\n    <\/p>\n<p>\n      <span class=\"bwuline\">The usual adult dose is an amount of lenvatinib in<br \/>\n      accordance with body weight administered orally once a day. For adults<br \/>\n      weighing 60 kg and over, the dose should be 12 mg. For adults weighing<br \/>\n      less than 60 kg, the dose should be 8 mg. The dose may be reduced<br \/>\n      depending on the condition of the individual patient.<\/span>\n    <\/p>\n<p>\n      <b>About LENVIMA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (lenvatinib mesylate)<br \/>\n      capsules, 10 mg and 4 mg<\/b>\n    <\/p>\n<p>\n      Discovered by Eisai, LENVIMA is an orally administered multiple receptor<br \/>\n      tyrosine kinase (RTK) inhibitor with a novel binding mode that<br \/>\n      selectively inhibits the kinase activities of vascular endothelial<br \/>\n      growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and<br \/>\n      fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4)<br \/>\n      in addition to other pathway-related RTKs (including the<br \/>\n      platelet-derived growth factor (PDGF) receptor PDGFR\u03b1; KIT; and RET)<br \/>\n      involved in tumor angiogenesis, tumor progression and modification of<br \/>\n      tumor immunity.\n    <\/p>\n<p>\n      Currently, LENVIMA is approved as a treatment for refractory thyroid<br \/>\n      cancer in over 50 countries, including the United States, Japan, in<br \/>\n      Europe and Asia. Additionally, Eisai has obtained approval for the agent<br \/>\n      in combination with everolimus as a treatment for renal cell carcinoma<br \/>\n      (second-line) in over 40 countries, including the United States and in<br \/>\n      Europe. In Europe, the agent was launched under the brand name Kisplyx<sup>\u00ae<\/sup><br \/>\n      for renal cell carcinoma.\n    <\/p>\n<p>\n      Outside of Japan, Eisai has submitted applications for an indication<br \/>\n      covering hepatocellular carcinoma in the United States and Europe (July<br \/>\n      2017), China (October 2017), Taiwan (December 2017) and other countries.\n    <\/p>\n<p>\n      <b>About the Eisai and Merck Strategic Collaboration<\/b>\n    <\/p>\n<p>\n      In March 2018, Eisai and Merck entered into a strategic collaboration<br \/>\n      for the worldwide co-development and co-commercialization of LENVIMA.<br \/>\n      Under the agreement, the companies will develop and commercialize<br \/>\n      LENVIMA jointly, both as monotherapy and in combination with Merck\u2019s<br \/>\n      anti-PD-1 therapy KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab). In addition to<br \/>\n      ongoing clinical studies of the combination, the companies will jointly<br \/>\n      initiate new clinical studies evaluating the LENVIMA\/KEYTRUDA<br \/>\n      combination to support 11 potential indications in six types of cancer<br \/>\n      (endometrial cancer, non-small cell lung cancer, hepatocellular<br \/>\n      carcinoma, head and neck cancer, bladder cancer and melanoma), as well<br \/>\n      as a basket trial targeting multiple cancer types.\n    <\/p>\n<p>\n      <b>About the REFLECT Study (Study 304)<\/b>\n    <\/p>\n<p>\n      The REFLECT study is a multicenter, open-label, randomized, global phase<br \/>\n      3 study comparing the efficacy and safety of LENVIMA versus sorafenib, a<br \/>\n      standard treatment for advanced HCC, as a first-line treatment for<br \/>\n      patients with unresectable HCC. In the study, 954 patients were<br \/>\n      randomized in a 1:1 ratio to receive LENVIMA 12 mg (\u226560 kg) or 8 mg (&lt;60<br \/>\n      kg) once a day, depending on baseline body weight (n=478), or sorafenib<br \/>\n      400 mg twice a day (n=476). Treatment was continued until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      The primary endpoint of the study was OS, with the goal of demonstrating<br \/>\n      non-inferiority. Other factors including PFS, TTP, ORR and QOL were<br \/>\n      assessed as secondary endpoints. According to the results of the study,<br \/>\n      LENVIMA met the statistical criteria for non-inferiority in the primary<br \/>\n      endpoint of median OS (13.6 months) compared to sorafenib (12.3 months)<br \/>\n      (HR 0.92, 95% CI=0.79-1.06).\n    <\/p>\n<p>\n      Additionally, LENVIMA showed statistically significant improvements in<br \/>\n      the three secondary efficacy endpoints (investigator assessment),<br \/>\n      doubling sorafenib&#8217;s median values and ratios: median PFS (LENVIMA 7.4<br \/>\n      months versus sorafenib 3.7 months [HR 0.66, 95% CI=0.57-0.77,<br \/>\n      p&lt;0.00001]), median TTP (LENVIMA 8.9 months versus sorafenib 3.7 months<br \/>\n      [HR 0.63, 95% CI=0.53-0.73, p&lt;0.00001]) and ORR (LENVIMA 24% versus<br \/>\n      sorafenib 9%, [p&lt;0.00001]).\n    <\/p>\n<p>\n      Furthermore, the European Organisation for Research and Treatment of<br \/>\n      Cancer&#8217;s (EORTC) health-related QOL questionnaires QLQ-C30 and QLQ-HCC18<br \/>\n      were used for the assessment. In both groups, scores decreased after the<br \/>\n      administration of the agents. However, within three categories in EORTC<br \/>\n      QLQ-C30 (role functioning, pain, diarrhea) and two categories in<br \/>\n      QLQ-HCC18 (nutrition, body image), it was found that LENVIMA helped to<br \/>\n      delay deterioration of QOL compared to sorafenib (nominal p-value&lt;0.05).\n    <\/p>\n<p>\n      In this study, the five most common adverse events observed in the<br \/>\n      LENVIMA arm were hypertension (42%), diarrhea (39%), decreased appetite<br \/>\n      (34%), weight loss (31%) and fatigue (30%), which is consistent with the<br \/>\n      known safety profile of LENVIMA.\n    <\/p>\n<p>\n      <b>LENVIMA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae <\/b><br \/>\n<\/sup><br \/>\n<b>(lenvatinib) Indications in the U.S.<\/b>\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae<\/sup> (lenvatinib) is a kinase inhibitor that is indicated<br \/>\n      for:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Differentiated Thyroid Cancer (DTC): single agent for patients with<br \/>\n        locally recurrent or metastatic, progressive, radioactive<br \/>\n        iodine-refractory DTC.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Renal Cell Cancer (RCC): in combination with everolimus for patients<br \/>\n        with advanced RCC following one prior anti-angiogenic therapy.\n      <\/li>\n<\/ul>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In DTC, hypertension was reported in 73% of patients on LENVIMA<br \/>\n        (lenvatinib) vs 16% with placebo (44% vs 4% grade \u22653). In RCC,<br \/>\n        hypertension was reported in 42% of patients on LENVIMA + everolimus<br \/>\n        vs 10% with everolimus alone (13% vs 2% grade 3). Serious<br \/>\n        complications of poorly controlled hypertension, including aortic<br \/>\n        dissection, have been reported. Systolic blood pressure \u2265160 mmHg<br \/>\n        occurred in 29% of patients, and 21% of patients had a diastolic blood<br \/>\n        pressure \u2265100 mmHg in the LENVIMA + everolimus\u2013treated group. Blood<br \/>\n        pressure should be controlled prior to treatment and monitored<br \/>\n        throughout. Withhold dose for grade 3 hypertension despite optimal<br \/>\n        antihypertensive therapy; resume at reduced dose when controlled at<br \/>\n        grade \u22642. Discontinue for life-threatening hypertension\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, cardiac dysfunction was reported in 7% of patients on LENVIMA<br \/>\n        vs 2% with placebo (2% vs 0% grade \u22653). In RCC, decreased ejection<br \/>\n        fraction and cardiac failure were reported in 10% of patients on<br \/>\n        LENVIMA + everolimus vs 6% with everolimus alone (3% vs 2% grade 3).<br \/>\n        Monitor for signs\/symptoms of cardiac decompensation. Withhold LENVIMA<br \/>\n        for development of grade 3 cardiac dysfunction until improvement to<br \/>\n        grade 0, 1, or baseline. Resume at reduced dose or discontinue based<br \/>\n        on severity and persistence of cardiac dysfunction. Discontinue for<br \/>\n        grade 4 cardiac dysfunction\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, arterial thromboembolic events were reported in 5% of patients<br \/>\n        on LENVIMA vs 2% with placebo (3% vs 1% grade \u22653). In RCC, arterial<br \/>\n        thromboembolic events were reported in 2% of patients on LENVIMA +<br \/>\n        everolimus vs 6% with everolimus alone (2% vs 4% grade \u22653).<br \/>\n        Discontinue following an arterial thrombotic event. The safety of<br \/>\n        resuming LENVIMA after an arterial thromboembolic event has not been<br \/>\n        established, and LENVIMA has not been studied in patients who have had<br \/>\n        an arterial thromboembolic event within the previous 6 months\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, hepatic failure (including fatal events) was reported in<br \/>\n        3 patients and acute hepatitis in 1 patient. In DTC, ALT and AST<br \/>\n        increases (grade \u22653) occurred in 4% and 5% of patients on LENVIMA,<br \/>\n        respectively, vs 0% with placebo. In RCC, ALT and AST increases (grade<br \/>\n        \u22653) occurred in 3% of patients on LENVIMA + everolimus vs 2% and 0%<br \/>\n        with everolimus alone, respectively. Monitor liver function before<br \/>\n        initiation, then every 2 weeks for the first 2 months, and at least<br \/>\n        monthly thereafter during treatment. Withhold dose for liver<br \/>\n        impairment grade \u22653 until resolved to grade 0, 1, or baseline. Resume<br \/>\n        at reduced dose or discontinue based on severity\/persistence of<br \/>\n        hepatotoxicity. Discontinue for hepatic failure\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, proteinuria was reported in 34% of patients on LENVIMA vs 3%<br \/>\n        with placebo (11% vs 0% grade 3). In RCC, proteinuria was reported in<br \/>\n        31% of patients on LENVIMA + everolimus vs 14% with everolimus alone<br \/>\n        (8% vs 2% grade 3). Monitor for proteinuria before and during<br \/>\n        treatment. Withhold dose for proteinuria \u22652 g\/24 h. Resume at reduced<br \/>\n        dose when proteinuria is&nbsp;&lt;2 g\/24 h. Discontinue for nephrotic syndrome\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, diarrhea was reported in 81% of patients on LENVIMA +<br \/>\n        everolimus vs 34% with everolimus alone (19% vs 2% grade \u22653). Initiate<br \/>\n        prompt medical management for the development of diarrhea. Monitor for<br \/>\n        dehydration. Withhold dose for diarrhea grade \u22653. Resume at a reduced<br \/>\n        dose when diarrhea resolves to grade 1 or baseline. Permanently<br \/>\n        discontinue LENVIMA for grade 4 diarrhea despite medical management\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, events of renal impairment were reported in 14% of patients on<br \/>\n        LENVIMA vs 2% with placebo (3% vs 1% grade \u22653). In RCC, events of<br \/>\n        renal impairment were reported in 18% of patients on LENVIMA +<br \/>\n        everolimus vs 12% with everolimus alone (10% vs 2% grade \u22653). Withhold<br \/>\n        LENVIMA for grade 3 or 4 renal failure\/impairment. Resume at reduced<br \/>\n        dose or discontinue, depending on severity\/persistence of renal<br \/>\n        impairment. Active management of diarrhea and any other<br \/>\n        gastrointestinal (GI) symptoms should be initiated for grade 1 events\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, events of GI perforation or fistula were reported in 2% of<br \/>\n        patients on LENVIMA vs 0.8% with placebo. In RCC, events of GI<br \/>\n        perforation, abscess, or fistula (grade \u22653) were reported in 2% of<br \/>\n        patients on LENVIMA (lenvatinib) + everolimus vs 0% with everolimus<br \/>\n        alone. Discontinue in patients who develop GI perforation or<br \/>\n        life-threatening fistula\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, QT\/QTc interval prolongation was reported in 9% of patients on<br \/>\n        LENVIMA vs 2% with placebo (2% vs 0% &gt;500 ms). In RCC, QTc interval<br \/>\n        increases &gt;60 ms were reported in 11% of patients on LENVIMA +<br \/>\n        everolimus (6% &gt;500 ms) vs 0% with everolimus alone. Monitor<br \/>\n        electrocardiograms in patients with congenital long QT syndrome,<br \/>\n        congestive heart failure, bradyarrhythmias, or patients taking drugs<br \/>\n        known to prolong the QT interval. Monitor and correct electrolyte<br \/>\n        abnormalities in all patients. Withhold dose for QTc interval<br \/>\n        prolongation &gt;500 ms. Resume at reduced dose when QTc prolongation<br \/>\n        resolves to baseline\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, hypocalcemia (grade \u22653) was reported in 9% of patients on<br \/>\n        LENVIMA vs 2% with placebo. In RCC, hypocalcemia (grade \u22653) was<br \/>\n        reported in 6% of patients on LENVIMA + everolimus vs 2% with<br \/>\n        everolimus alone. Monitor blood calcium levels at least monthly and<br \/>\n        replace calcium as necessary. Interrupt and adjust LENVIMA as necessary\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, reversible posterior leukoencephalopathy syndrome (RPLS)<br \/>\n        was reported in 4 patients. Withhold LENVIMA for RPLS until fully<br \/>\n        resolved. Resume at reduced dose or discontinue based on the severity<br \/>\n        and persistence of neurologic symptoms\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Across clinical studies in which 1,160 patients received LENVIMA<br \/>\n        monotherapy, hemorrhage (grade \u22653) was reported in 2% of patients. In<br \/>\n        DTC, hemorrhagic events occurred in 35% of patients on LENVIMA vs 18%<br \/>\n        with placebo (2% vs 3% grade \u22653). There was 1 fatal intracranial<br \/>\n        hemorrhage case among 16 patients who received LENVIMA and had central<br \/>\n        nervous system metastases at baseline. The most frequently reported<br \/>\n        hemorrhagic event was epistaxis (11% grade 1, 1% grade 2).<br \/>\n        Discontinuation due to hemorrhagic events occurred in 1% of patients<br \/>\n        on LENVIMA. In RCC, hemorrhagic events occurred in 34% of patients on<br \/>\n        LENVIMA + everolimus vs 26% with everolimus alone (8% vs 2% grade \u22653).<br \/>\n        The most frequently reported hemorrhagic event was epistaxis (23% for<br \/>\n        LENVIMA + everolimus vs 24% with everolimus alone). There was 1 fatal<br \/>\n        cerebral hemorrhage case. Discontinuation due to hemorrhagic events<br \/>\n        occurred in 3% of patients on LENVIMA + everolimus. Consider the risk<br \/>\n        of severe or fatal hemorrhage associated with tumor<br \/>\n        invasion\/infiltration of major blood vessels (eg, carotid artery).<br \/>\n        Withhold LENVIMA for the development of grade 3 hemorrhage until<br \/>\n        resolved to grade 0 or 1. Resume at reduced dose or discontinue based<br \/>\n        on severity\/persistence of hemorrhage. Discontinue for grade 4<br \/>\n        hemorrhage\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC patients with normal baseline thyroid-stimulating hormone<br \/>\n        (TSH), elevation of TSH level above 0.5 mU\/L was observed postbaseline<br \/>\n        in 57% of patients on LENVIMA vs 14% with placebo. In RCC, grade 1 or<br \/>\n        2 hypothyroidism occurred in 24% of patients on LENVIMA + everolimus<br \/>\n        vs 2% with everolimus alone. In RCC patients with normal or low TSH at<br \/>\n        baseline, elevation of TSH was observed postbaseline in 60% of<br \/>\n        patients on LENVIMA + everolimus vs 3% with everolimus alone. Monitor<br \/>\n        thyroid function before initiation of and at least monthly throughout<br \/>\n        treatment. Treat hypothyroidism according to standard medical practice<br \/>\n        to maintain a euthyroid state\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Impaired wound healing, including fistula formation, has been reported<br \/>\n        in patients receiving LENVIMA. Temporary interruption of LENVIMA<br \/>\n        therapy should be considered in patients undergoing major surgical<br \/>\n        procedures\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        LENVIMA can cause fetal harm when administered to a pregnant woman.<br \/>\n        Advise females of reproductive potential to use effective<br \/>\n        contraception during treatment with LENVIMA and for at least 2 weeks<br \/>\n        following completion of therapy\n      <\/li>\n<\/ul>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In DTC, the most common adverse reactions (\u226530%) observed in<br \/>\n        LENVIMA-treated patients vs placebo-treated patients were hypertension<br \/>\n        (73% vs 16%), fatigue (67% vs 35%), diarrhea (67% vs 17%),<br \/>\n        arthralgia\/myalgia (62% vs 28%), decreased appetite (54% vs 18%),<br \/>\n        weight decrease (51% vs 15%), nausea (47% vs 25%), stomatitis (41% vs<br \/>\n        8%), headache (38% vs 11%), vomiting (36% vs 15%), proteinuria (34% vs<br \/>\n        3%), palmar-plantar erythrodysesthesia syndrome (32% vs 1%), abdominal<br \/>\n        pain (31% vs 11%), and dysphonia (31% vs 5%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In DTC, adverse reactions led to dose reductions in 68% of patients<br \/>\n        receiving LENVIMA (lenvatinib) and in 5% of patients receiving<br \/>\n        placebo; 18% of patients discontinued LENVIMA and 5% discontinued<br \/>\n        placebo for adverse reactions. The most common adverse reactions<br \/>\n        (\u226510%) resulting in dose reductions of LENVIMA were hypertension<br \/>\n        (13%), proteinuria (11%), decreased appetite (10%), and diarrhea<br \/>\n        (10%); the most common adverse reactions (\u22651%) resulting in<br \/>\n        discontinuation of LENVIMA were hypertension (1%) and asthenia (1%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, the most common adverse reactions (&gt;30%) observed in patients<br \/>\n        treated with LENVIMA + everolimus vs everolimus alone were diarrhea<br \/>\n        (81% vs 34%), fatigue (73% vs 40%), arthralgia\/myalgia (55% vs 32%),<br \/>\n        decreased appetite (53% vs 18%), vomiting (48% vs 12%), nausea (45% vs<br \/>\n        16%), stomatitis\/oral inflammation (44% vs 50%),<br \/>\n        hypertension\/increased blood pressure (42% vs 10%), peripheral edema<br \/>\n        (42% vs 20%), cough (37% vs 30%), abdominal pain (37% vs 8%),<br \/>\n        dyspnea\/exertional dyspnea (35% vs 28%), rash (35% vs 40%), weight<br \/>\n        decreased (34% vs 8%), hemorrhagic events (32% vs 26%), and<br \/>\n        proteinuria\/urine protein present (31% vs 14%). The most common<br \/>\n        serious adverse reactions (\u22655%) were renal failure (11%), dehydration<br \/>\n        (10%), anemia (6%), thrombocytopenia (5%), diarrhea (5%), vomiting<br \/>\n        (5%), and dyspnea (5%)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In RCC, adverse reactions led to dose reductions or interruption in<br \/>\n        89% of patients receiving LENVIMA&nbsp;+&nbsp;everolimus and in 54% of patients<br \/>\n        receiving everolimus alone. The most common adverse reactions (\u22655%)<br \/>\n        resulting in dose reductions in the LENVIMA&nbsp;+&nbsp;everolimus\u2013treated group<br \/>\n        were diarrhea (21%), fatigue (8%), thrombocytopenia (6%), vomiting<br \/>\n        (6%), nausea (5%), and proteinuria (5%). Treatment discontinuation due<br \/>\n        to an adverse reaction occurred in 29% of patients in the<br \/>\n        LENVIMA&nbsp;+&nbsp;everolimus\u2013treated group and in 12% of patients in the<br \/>\n        everolimus-treated group\n      <\/li>\n<\/ul>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Because of the potential for serious adverse reactions in nursing<br \/>\n        infants, advise women to discontinue breastfeeding during treatment\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        LENVIMA may result in reduced fertility in females of reproductive<br \/>\n        potential and may result in damage to male reproductive tissues,<br \/>\n        leading to reduced fertility of unknown duration\n      <\/li>\n<\/ul>\n<p>\n      For more information about LENVIMA, click <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lenvima.com%2Fpdfs%2Fprescribing-information.pdf%3Futm_source%3Dpr%26utm_medium%3Dweb%26utm_content%3DpiP4%26utm_campaign%3Drcclaunch&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=53629fb2d720a6b2b5266ebead4cfe6c\" rel=\"nofollow\">here<\/a><br \/>\n      for the full Prescribing Information.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes,<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing in the U.S.<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab), as a single agent, is indicated for the<br \/>\n      first-line treatment of patients with metastatic non-small cell lung<br \/>\n      cancer (NSCLC) whose tumors have high PD-L1 expression [tumor proportion<br \/>\n      score (TPS) \u226550%] as determined by an FDA-approved test, with no EGFR or<br \/>\n      ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA (pembrolizumab) is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression. In pediatric patients with cHL, KEYTRUDA is<br \/>\n      administered at a dose of 2 mg\/kg (up to a maximum of 200 mg) every<br \/>\n      three weeks until disease progression or unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA (pembrolizumab) in pediatric patients with<br \/>\n      MSI-H central nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer,\n    <\/p>\n<p>\n      KEYTRUDA is administered at a dose of 2 mg\/kg (up to a maximum of 200<br \/>\n      mg) every three weeks until disease progression or unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity, or up to<br \/>\n      24 months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA (pembrolizumab) for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.3%) thyroiditis. Monitor patients for changes in thyroid<br \/>\n      function (at the start of treatment, periodically during treatment, and<br \/>\n      as indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) and administer corticosteroids. For signs or<br \/>\n      symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for<br \/>\n      specialized care for assessment and treatment. If SJS or TEN is<br \/>\n      confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA<br \/>\n      (pembrolizumab). Of 23 patients with cHL who proceeded to allogeneic<br \/>\n      HSCT after treatment with KEYTRUDA on any trial, 6 patients (26%)<br \/>\n      developed graft-versus-host disease (GVHD), one of which was fatal, and<br \/>\n      2 patients (9%) developed severe hepatic veno-occlusive disease (VOD)<br \/>\n      after reduced-intensity conditioning, one of which was fatal. Cases of<br \/>\n      fatal hyperacute GVHD after allogeneic HSCT have also been reported in<br \/>\n      patients with lymphoma who received a PD-1 receptor\u2013blocking antibody<br \/>\n      before transplantation.\n    <\/p>\n<p>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 23% of patients; the most common (\u22651%) were<br \/>\n      diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation<br \/>\n      (1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most common<br \/>\n      adverse reactions (occurring in at least 20% of patients and at a higher<br \/>\n      incidence than with docetaxel) were decreased appetite (25% vs 23%),<br \/>\n      dyspnea (23% vs 20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      In KEYNOTE-021(G1), when KEYTRUDA (pembrolizumab) was administered in<br \/>\n      combination with carboplatin and pemetrexed (carbo\/pem) in advanced<br \/>\n      nonsquamous NSCLC, KEYTRUDA was discontinued in 10% of 59 patients. The<br \/>\n      most common adverse reaction resulting in discontinuation of KEYTRUDA<br \/>\n      (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading to<br \/>\n      interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%). The most common adverse<br \/>\n      reactions (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue<br \/>\n      (71% vs 50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42%<br \/>\n      vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs<br \/>\n      23%), decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24%<br \/>\n      vs 18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA (pembrolizumab) was discontinued due to adverse<br \/>\n      reactions in 11% of 370 patients with locally advanced or metastatic<br \/>\n      urothelial carcinoma. The most common adverse reactions (in \u226520% of<br \/>\n      patients) were fatigue (38%), musculoskeletal pain (24%), decreased<br \/>\n      appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).<br \/>\n      Eighteen patients (5%) died from causes other than disease progression.<br \/>\n      Five patients (1.4%) who were treated with KEYTRUDA experienced sepsis<br \/>\n      which led to death, and 3 patients (0.8%) experienced pneumonia which<br \/>\n      led to death. Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 22% of patients; the most common (\u22651%) were liver enzyme<br \/>\n      increase, diarrhea, urinary tract infection, acute kidney injury,<br \/>\n      fatigue, joint pain, and pneumonia. Serious adverse reactions occurred<br \/>\n      in 42% of patients, the most frequent (\u22652%) of which were urinary tract<br \/>\n      infection, hematuria, acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1\u201317 doses), with 34<br \/>\n      patients (85%) receiving KEYTRUDA for 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults<br \/>\n      treated with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf+&amp;index=2&amp;md5=086e31903122dc744f7c9c1cffddbf19\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<br \/>\n      <\/a><br \/>\n<b>and Patient Information\/Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=3&amp;md5=ec81256d07b703a47c8bff3cfad2c157\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/a>\n    <\/p>\n<p>\n      <b>Eisai\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Eisai regards oncology as a key therapeutic area and is aiming to<br \/>\n      discover revolutionary new medicines with the potential to cure cancer<br \/>\n      by leveraging drug creation base technologies cultivated through the<br \/>\n      discovery of LENVIMA and Halaven, as well as technologies associated<br \/>\n      with organic synthetic chemistry and drug discovery science. Eisai\u2019s<br \/>\n      research groups in Japan and the United States are working on drug<br \/>\n      discovery activities using drug discovery platforms mainly for the<br \/>\n      cancer microenvironment, driver gene mutation and aberrant splicing in<br \/>\n      cancer cells, that are Eisai\u2019s strengths.\n    <\/p>\n<p>\n      <b>About Eisai Co., Ltd.<\/b>\n    <\/p>\n<p>\n      Eisai Co., Ltd. is a leading global research and development-based<br \/>\n      pharmaceutical company headquartered in Japan. We define our corporate<br \/>\n      mission as \u201cgiving first thought to patients and their families and to<br \/>\n      increasing the benefits health care provides,\u201d which we call our <i>human<br \/>\n      health care<\/i> (<i>hhc<\/i>) philosophy. With approximately 10,000<br \/>\n      employees working across our global network of R&amp;D facilities,<br \/>\n      manufacturing sites and marketing subsidiaries, we strive to realize our <i>hhc<\/i><br \/>\n      philosophy by delivering innovative products in various therapeutic<br \/>\n      areas with high unmet medical needs, including Oncology and Neurology.\n    <\/p>\n<p>\n      As a global pharmaceutical company, our mission extends to patients<br \/>\n      around the world through our investment and participation in<br \/>\n      partnership-based initiatives to improve access to medicines in<br \/>\n      developing and emerging countries.\n    <\/p>\n<p>\n      For more information about Eisai Co., Ltd., please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.eisai.com&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=www.eisai.com&amp;index=4&amp;md5=29f341c77fa63bf6e60bcec6caa84858\" rel=\"nofollow\">www.eisai.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=5&amp;md5=688ecb9702228b37e015444ac6b1f89c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world \u2013 including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=6&amp;md5=571b85d57f94fa7a65d713f598c4b496\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=Twitter&amp;index=7&amp;md5=fc794b63718b270c30fdf609516ccf9f\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=Facebook&amp;index=8&amp;md5=a12b3edaddc303654ba329816a64b19d\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=Instagram&amp;index=9&amp;md5=c84d3b9eac8ee89447d7815e922b4ab3\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=YouTube&amp;index=10&amp;md5=6f264ae24f88caa96f494b0904bf5794\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=11&amp;md5=96d4907458e7d08dc2a1f9e8b47bbc74\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51777927&amp;newsitemid=20180323005179&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=12&amp;md5=0e786af28e9c4b79cb35889c52d9e40a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180323005179r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Eisai Public Relations Department <br \/>+81-(0)3-3817-5120<br \/>or<br \/> Eisai        Investor Relations <br \/>+81-(0)3-3817-3016<br \/>or<br \/> Merck        Media Relations <br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Ann        Bush, 908-740-6677<br \/>or<br \/> Merck Investor Relations <br \/>Teri        Loxam, 908-740-1986<br \/>or<br \/>Peter Dannenbaum, 908-740-1037     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>First New Front-Line Treatment Option for HCC Approved in Japan in Nearly 10 Years First Approval Under Global Strategic Collaboration Between Eisai Co., Ltd. and Merck Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA \u00ae (lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front line treatment of HCC in approximately 10 years. Additionally, this is the first regulatory approval for LENVIMA under the global strategic collaboration agreement executed in March 2018 between Eisai and Merck for the co-development and co-commercialization of LENVIMA. This approval was based on a phase 3 clinical study (Study 304\/REFLECT study) conducted by Eisai investigating LENVIMA as a<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289],"class_list":["post-745745","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com\" \/>\n<meta property=\"og:description\" content=\"First New Front-Line Treatment Option for HCC Approved in Japan in Nearly 10 Years First Approval Under Global Strategic Collaboration Between Eisai Co., Ltd. and Merck Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA \u00ae (lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front line treatment of HCC in approximately 10 years. Additionally, this is the first regulatory approval for LENVIMA under the global strategic collaboration agreement executed in March 2018 between Eisai and Merck for the co-development and co-commercialization of LENVIMA. This approval was based on a phase 3 clinical study (Study 304\/REFLECT study) conducted by Eisai investigating LENVIMA as a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"33 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\\\/\",\"name\":\"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-03-23T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:27:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/","og_locale":"en_US","og_type":"article","og_title":"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com","og_description":"First New Front-Line Treatment Option for HCC Approved in Japan in Nearly 10 Years First Approval Under Global Strategic Collaboration Between Eisai Co., Ltd. and Merck Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA \u00ae (lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front line treatment of HCC in approximately 10 years. Additionally, this is the first regulatory approval for LENVIMA under the global strategic collaboration agreement executed in March 2018 between Eisai and Merck for the co-development and co-commercialization of LENVIMA. This approval was based on a phase 3 clinical study (Study 304\/REFLECT study) conducted by Eisai investigating LENVIMA as a","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:25+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"33 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/","name":"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-03-23T06:00:00+00:00","dateModified":"2025-11-07T06:27:25+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/anticancer-agent-lenvima-lenvatinib-mesylate-approved-for-additional-indication-of-unresectable-hepatocellular-carcinoma-hcc-in-japan-first-approval-worldwide-for-lenvima-for-hcc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Anticancer Agent LENVIMA\u00ae (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"fd215cae-4f6a-4d2f-b593-820b17c02246","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/03\/1\/244698_merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/03\/1\/Eisai_Logo.jpg","size":"78853","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Anticancer-Agent-LENVIMA-lenvatinib-mesylate-Approved-for-Additional-Indication-of-Unresectable-Hepatocellular-Carcinoma-HCC-in-Japan-UGEM8.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745745\/revisions"}],"predecessor-version":[{"id":3675108,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745745\/revisions\/3675108"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745745"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}